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step, images that represent the center of medial compartment
are selected. 2) Then, the image is converted into black-and-
white image. Threshold between black and white is determined
by the software. 3) Lastly, the contour of MFC is extracted and
four parameters are calculated automatically: a) the average
thickness of the subchondral bone plate (ATS: tentative units),
the ratio of the length of upper surface and the lower surface of
the subchondral bone plate (RUL), c) average squared thickness
of the subchondral bone plate (ASTS) and d) standard deviation
of the thickness of the subchondral bone (SDS). The more se-
vere the irregularity becomes the larger ATS, RUL, ASTS and
SDS become. Correlation between those parameters and clinical
score were analyzed using Pearson’s correlation coefficient.
Results: The data of four parameters were as follows. ATS: 3.34
to 16.42 (ave. 7.01), RUL: 0.980 to 1.536 (ave. 1.165), ASTS:
14.63 to 382.21(ave. 69.70) and SDS: 1.258 to 7.991 (ave.
3.504). ATS, RUL, ASTS and SDS were statistically significant
correlation with Lysholm score (p<0.05).
Conclusions: We have concluded that 1) ATS, RUL, ASTS and
SDS could serve as an objective index that indicating disease
severity of OA; 2) pathological state of subchondral bone plate
was one of the biggest factors to determine the severity of OA;
3) ATS, RUL, ASTS and SDS reflected the pathological state of
subchondral bone area; and 4) ATS, RUL, ASTS and SDS could
be a objective determinant when selecting treatment option.
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Purpose: Osteophytes (OST), which develop through endochon-
dral ossification often at sites of adjacent cartilage loss, are key
features of osteoarthritis (OA). OST in the spine are accompa-
nied by OST in peripheral joints and agents that affect OST in
the spine may potentially affect OST elsewhere in the body. We
evaluated the effect of the bisphosphonate alendronate (ALN)
on the progression of radiographic spinal OST in a secondary
analysis of the Fracture Intervention Trial (FIT).
Methods: FIT was a large (n=6463) randomized placebo-
controlled trial evaluating the effectiveness of ALN at 5 mg/d
(1st 2 years) followed by 10 mg/d thereafter vs placebo (PBO)
over 3-4 years (3 for those with prevalent vertebral fractures
(VtFx), 4 for those without one) in preventing osteoporotic frac-
tures in postmenopausal women with prevalent VtFx or low bone
mass. In a random sample of 200 participants, stratified by age
(<65 vs. ≥65) and presence of baseline VtFx, we read baseline
and follow-up lateral spine x-rays for anterior OST (scored 0-3 on
the superior and inferior aspects of each vertebral body) in the
thoracic (T4-T12) and lumbar (L1-L5) spine (ICC for lumbar=0.88
and for thoracic=0.97), blinded to treatment. We calculated the
sum of OST scores from T4 to L5 at baseline and follow-up. We
evaluated the mean difference in change from baseline to fol-
lowup in the summary OST score between treatment arms using
linear regression and performed separate analyses in which we
additionally adjusted for age, BMI, presence of baseline VtFx,
presence of incident VtFx, baseline kyphosis score, and pres-
ence of diabetes at baseline.
Results: The baseline characteristics of the participants were
similar in ALN and PBO arms (Table 1). The mean change in
summary OST score was significantly less in the ALN group com-
Table 1. Baseline Characteristics
Variable ALN (n=84) PBO (n=116)
Age [mean ± SD (range)] 68.5 ± 6.1 (55-79) 66.1 ± 6.4 (55-80)
Age ≥65 [n (%)] 39 (46.3) 55 (47.1)
BMI [mean ± SD] 24.8 ± 4.2 25.3 ± 3.9
Diabetes [n (%)] 4 (4.8) 5 (4.4)
Baseline Vertebral Fracture [n (%)] 50 (59.5) 64 (55.2)
Incident Vertebral Fracture [n (%)] 5 (6.0) 9 (7.8)
Baseline summary OST score
[mean ± SD (range)] 15.7 ± 9.2 (1-52) 15.5 ± 8.8 (2-49)
Table 2. Change in summary OST score
ALN (n=84) PBO (n=116)
Unadjusted change in summary
OST score [mean ± SE] 3.1 ± 0.4 4.8 ± 0.5 P=0.02
Adjusted* change in summary
OST score [mean ± SE] 3.2 ± 0.4 4.8 ± 0.5 P=0.03
*Adjusted for age, BMI, diabetes, baseline vertebral fracture, incident vertebral
fracture, baseline kyphosis score.
pared to the PBO group (p=0.02) (Table 2), indicating that OST
progression was less in the ALN group. The results remained the
same after multivariable adjustment for potential confounders.
There was no evidence of interaction between treatment as-
signment and presence of baseline or incident VtFx (p=0.3 and
0.7 respectively) suggesting that the prevention of VtFx did not
cause the inhibition of OST growth.
Conclusions: In this pilot study of the effect of ALN vs PBO
on progression of spinal OST from a randomized clinical trial in
older women, ALN was associated with less OST progression
than PBO. This suggests a role for bisphosphonates in altering
the process of OST formation which may be due to direct effects
on endochondral ossification processes or on OA.
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Purpose: Intra-articular injection of hyaluronan (HA)-based vis-
cosupplements is a local therapy for the treatment of pain due to
osteoarthritis. HA is a major component of synovial fluid that pro-
vides shock absorption, joint lubrication and cartilage protection
to the joint. The purpose of these studies was to compare the
physical and histological properties of two crosslinked HA-based
visocosupplements. One of them is NASHA (non-animal stabi-
lized hyaluronic acid) which is an epoxy crosslinked product, and
the other is hylan G-F 20, a divinyl sulfone crosslinked product.
The physical properties including rheology and dilution durability
of the products were evaluated. The biological reactivity of the
products was also evaluated using a muscle implant test.
Methods: The rheological properties of the products, such as
modulus, phase angle, rupture stress and viscosity were as-
sessed by the oscillation and viscometry tests of a control stress
rheometer. For the dilution durability test, the products were di-
luted with buffered saline and the rheological properties were
determined for each dilution. The maximum dilution at which the
percent phase angle increase continued to be ≤ 50% was de-
fined as the product’s dilution durability. The biological reactivity
of the two products was compared with high density polyethylene
(HDPE) as a control. The response to each product was eval-
uated macroscopically and microscopically in a rabbit muscle
implant model at 7 days and 4 weeks after implantation.
Results: NASHA showed a much higher modulus, but much
lower rupture stress (Table 1) than hylan G-F 20. Results sug-
